The best GLP-1 for weight loss depends on what you are optimizing for. If total pounds lost is the priority, tirzepatide (Zepbound) wins: in the SURMOUNT-1 trial, adults on the 15 mg dose lost about 21 percent of body weight over 72 weeks, versus roughly 15 percent for semaglutide 2.4 mg (Wegovy) in STEP-1 and about 5 to 6 percent for liraglutide 3.0 mg (Saxenda) over 56 weeks. If cost, insurance coverage, or tolerability matter more than peak effect, semaglutide or an older agent may be the smarter choice. No single drug is best for every person.
What GLP-1 Drugs Actually Do Inside the Body
GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after you eat. Natural GLP-1 has a half-life of under two minutes because an enzyme called DPP-4 destroys it almost immediately. Every drug in this class solves that problem by resisting DPP-4 breakdown, which stretches a two-minute signal into a 7-day (semaglutide) or 5-day (tirzepatide) one.
The weight loss comes from three mechanisms working together. First, these drugs bind receptors in the hypothalamus and brainstem, reducing appetite signaling. Second, they slow gastric emptying, so food sits in the stomach longer and you feel full sooner. Third, they improve satiety signaling after meals, which reduces the drive to snack.
Tirzepatide adds a fourth lever. It is a dual GIP/GLP-1 receptor agonist, meaning it also mimics glucose-dependent insulinotropic polypeptide. GIP receptors in adipose tissue and the brain appear to amplify the appetite-suppression effect and may improve how fat cells handle energy storage.
In plain terms: semaglutide turns down hunger; tirzepatide turns down hunger and adds a second chemical signal that appears to turn up fat metabolism. That extra receptor is the main reason tirzepatide produces larger average weight loss.
One important correction to a common misconception: these are not "fat burners." They do not directly destroy fat cells, and they do not work if appetite suppression is ignored. The weight comes off because caloric intake falls, driven by reduced hunger. That distinction matters for what happens after you stop.
Head-to-Head Numbers: How the Three Main Options Compare
The table below reconciles the major clinical trial results. Note that cross-trial comparisons are imperfect because populations, run-in periods, and diet counseling differed, but the magnitude gap is large enough that the ranking is reliable.
| Drug (brand) | Receptor target | Top dose | Trial | Average weight loss | Duration | Common GI side effects |
|---|---|---|---|---|---|---|
| Tirzepatide (Zepbound) | GIP + GLP-1 | 15 mg weekly | SURMOUNT-1 | ~21% | 72 weeks | Nausea ~25%, diarrhea ~20% |
| Semaglutide (Wegovy) | GLP-1 | 2.4 mg weekly | STEP-1 | ~15% | 68 weeks | Nausea ~44%, diarrhea ~30% |
| Liraglutide (Saxenda) | GLP-1 | 3.0 mg daily | SCALE | ~5-6% | 56 weeks | Nausea ~40%, vomiting ~16% |
| Semaglutide oral (Rybelsus) | GLP-1 | 25 mg daily* | OASIS 4 | ~13-14% | 64 weeks | Nausea ~20-30% |
*Oral semaglutide dosing for weight management is distinct from the diabetes dose; confirm current labeling with your prescriber.
The gap between tirzepatide and semaglutide is roughly 6 percentage points of body weight. For a 220-pound adult, that is about 13 additional pounds. The gap between semaglutide and liraglutide is much larger, roughly 9 to 10 percentage points, which is why liraglutide is now considered a third-line option in most guidelines.
A quantified detail that rarely appears in consumer reviews: the number-needed-to-treat. In SURMOUNT-1, about 36 percent of participants on 15 mg tirzepatide lost 25 percent or more of body weight. In STEP-1, the comparable figure for semaglutide 2.4 mg was roughly 14 percent. That means for every 100 patients treated, tirzepatide produces about 22 more people in the 25-percent-loss tier than semaglutide.
The Timeline: When Weight Loss Actually Happens
Weight loss on GLP-1 drugs is not linear, and knowing the curve prevents premature quitting. Most people lose the fastest weight in the first 16 to 20 weeks, then plateau as the dose stabilizes and the body adapts.
| Time on drug | What typically happens | Expected cumulative loss (tirzepatide 15 mg) | Expected cumulative loss (semaglutide 2.4 mg) |
|---|---|---|---|
| Weeks 1-4 | Titration starts; GI side effects peak | 2-4% | 1-3% |
| Weeks 5-12 | Appetite suppression stabilizes | 6-9% | 4-6% |
| Weeks 13-24 | Fastest loss phase | 12-16% | 8-11% |
| Weeks 25-40 | Loss slows; plateau begins | 18-20% | 12-14% |
| Weeks 41-72 | Maintenance plateau | 20-22% | 14-16% |
| After stopping | Appetite returns within 1-2 weeks | Regain of ~two-thirds within 1 year | Similar pattern |
The regain figure comes from the STEP-1 extension study, where participants off semaglutide regained about two-thirds of lost weight within a year. This is not a failure of willpower; it is the predictable result of removing a hormone signal the brain had adapted to. Any honest comparison of GLP-1 options must include the discontinuation scenario.
Edge Cases and Variations That Change the Answer
The "best" drug shifts for specific populations. These are the variations that matter most.
Kidney function. Semaglutide has dedicated cardiovascular and kidney outcome data (the FLOW trial showed a 24 percent reduction in major kidney events in people with type 2 diabetes and chronic kidney disease). Tirzepatide has strong cardiovascular data in SURPASS-CVOT but less dedicated kidney-outcome evidence. For a patient with CKD, semaglutide's evidence base is deeper.
Cardiovascular history. Both semaglutide and tirzepatide have shown cardiovascular benefit in large trials. Liraglutide also has cardiovascular outcome data (LEADER), which is why it retains a niche for patients with established heart disease who cannot access newer agents.
Tolerability. Nausea is the most common reason people stop. Semaglutide's GI side-effect rates run higher than tirzepatide's in head-to-head indirect comparisons, which is counterintuitive given tirzepatide's greater efficacy. A patient who cannot tolerate 2.4 mg semaglutide may do better on tirzepatide at a lower dose, and vice versa.
Cost and access. As of late 2026, list prices remain in the USD 900 to USD 1,300 per month range for brand-name injectables without insurance. Compounded versions exist but are not FDA-approved and carry quality risk. Oral semaglutide is often cheaper per month, which changes the calculus for uninsured patients.
Three Misconceptions Worth Correcting
The first misconception is that higher dose always means more weight loss. In SURMOUNT-1, the 5 mg tirzepatide dose produced about 15 percent weight loss, roughly matching semaglutide 2.4 mg. If you cannot tolerate the top dose, you may land at semaglutide-equivalent results anyway. The dose-response curve flattens above about 10 mg for tirzepatide.
The second misconception is that these drugs replace diet and exercise. They do not. In every major trial, participants received structured diet and physical activity counseling. The drug makes adherence to a calorie deficit possible; it does not create the deficit by itself. Patients who stop counseling and rely on the drug alone tend to plateau earlier.
The third misconception is that "natural" GLP-1 supplements work. They do not. Oral GLP-1 is broken down in the stomach within minutes. The only oral GLP-1 drug that works (Rybelsus) uses a specialized absorption enhancer (SNAC) to get a tiny fraction of the dose into the bloodstream, and even then bioavailability is under 1 percent. Anyone selling a "GLP-1 booster" capsule is selling a story, not a mechanism.
What to Actually Do If You Are Choosing a GLP-1
Start with your prescriber, not with a review site, but arrive prepared. These are the concrete steps that improve outcomes.
- Confirm your BMI and any weight-related conditions. Most insurers require a BMI of 30 or higher, or 27 with at least one comorbidity such as hypertension or prediabetes.
- Ask specifically about tirzepatide versus semaglutide head-to-head for your profile, including kidney and cardiovascular history.
- Request a titration schedule in writing. Going up too fast is the leading cause of intolerable nausea.
- Set a protein target of 1.2 to 1.6 grams per kilogram of body weight daily. Rapid weight loss on these drugs includes lean mass, and protein plus resistance training preserves it.
- Plan the discontinuation conversation before you start. Ask what maintenance looks like and whether a lower dose can hold results.
- Track side effects weekly for the first 12 weeks. Red-flag symptoms below warrant a call to your prescriber.
Seek urgent medical attention for these warning signs:
- Severe abdominal pain radiating to the back (possible pancreatitis)
- Persistent vomiting preventing fluid intake
- Signs of gallbladder disease: right-upper-quadrant pain, fever, jaundice
- Vision changes (rare but reported with rapid glucose lowering)
- Severe dehydration or dizziness on standing
Limitations of the Evidence and What We Still Do Not Know
No head-to-head randomized trial has directly compared tirzepatide 15 mg to semaglutide 2.4 mg for weight loss as of November 2026. The SURMOUNT-5 trial, which does compare them directly, has reported preliminary results favoring tirzepatide, but full peer-reviewed publication is still pending. Until that data is fully available, the ranking above rests on cross-trial comparison, which is informative but not definitive.
We also lack long-term data beyond about four years for the newest agents. We do not know whether the cardiovascular and kidney benefits persist after discontinuation, or whether weight regain reverses them. We do not know the long-term effects on lean mass in older adults, a population at higher risk of sarcopenia. And we do not have robust data on cycling between agents or using combination therapy.
One more limitation deserves emphasis: trial populations were predominantly white and female, with limited representation of older adults and people with severe obesity (BMI above 40). Real-world results in those groups may differ. The honest answer to "which is best" is that tirzepatide currently leads on average weight loss, semaglutide leads on breadth of outcome evidence, and the right choice depends on your specific comorbidities, tolerance, and access.